Biogen Inc. (ETR:IDP)
159.95
-0.70 (-0.44%)
Jan 12, 2026, 11:18 AM CET
Biogen Revenue
Biogen had revenue of $2.53B USD in the quarter ending September 30, 2025, with 2.79% growth. This brings the company's revenue in the last twelve months to $10.07B, up 4.77% year-over-year. In the year 2024, Biogen had annual revenue of $9.68B, down -1.62%.
Revenue (ttm)
$10.07B
Revenue Growth
+4.77%
P/S Ratio
2.76
Revenue / Employee
$1.32M
Employees
7,605
Market Cap
23.66B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.68B | -159.70M | -1.62% |
| Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
| Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
| Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
| Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
| Dec 31, 2019 | 14.38B | 925.00M | 6.88% |
| Dec 31, 2018 | 13.45B | 1.18B | 9.61% |
| Dec 31, 2017 | 12.27B | 825.10M | 7.21% |
| Dec 31, 2016 | 11.45B | 685.00M | 6.36% |
| Dec 31, 2015 | 10.76B | 1.06B | 10.93% |
| Dec 31, 2014 | 9.70B | 2.77B | 39.97% |
| Dec 31, 2013 | 6.93B | 1.42B | 25.66% |
| Dec 31, 2012 | 5.52B | 467.83M | 9.27% |
| Dec 31, 2011 | 5.05B | 332.21M | 7.04% |
| Dec 31, 2010 | 4.72B | 339.08M | 7.75% |
| Dec 31, 2009 | 4.38B | 279.84M | 6.83% |
| Dec 31, 2008 | 4.10B | 925.89M | 29.19% |
| Dec 31, 2007 | 3.17B | 488.57M | 18.21% |
| Dec 31, 2006 | 2.68B | 260.55M | 10.76% |
| Dec 31, 2005 | 2.42B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 45.87B |
| Siemens Healthineers AG | 23.38B |
| Fresenius SE & Co. KGaA | 22.45B |
| Merck KGaA | 21.27B |
| Fresenius Medical Care AG | 19.64B |
| Sartorius Aktiengesellschaft | 3.52B |
| Redcare Pharmacy NV | 2.82B |
| Fielmann Group AG | 2.42B |
Biogen News
- 10 days ago - Samsung Bioepis Co., Ltd.: Samsung Bioepis Begins Commercialization of BYOOVIZ, Biosimilar to Lucentis (Ranibizumab), in Europe - Finanz Nachrichten
- 12 days ago - Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge - Seeking Alpha
- 18 days ago - Is Biogen Inc Gaining or Losing Market Support? - Benzinga
- 20 days ago - JAMA Neurology Data Shows Meaningful Effects With Biogen's QALSODY In Long-Term Results - Nasdaq
- 20 days ago - Biogen (BIIB) Phase 3 Study Highlights Benefits of QALSODY in ALS Treatment - GuruFocus
- 20 days ago - Biogen Inc.: The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS - Finanz Nachrichten
- 20 days ago - The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS - GlobeNewsWire
- 23 days ago - Biogen (BMRN) to Acquire Amicus Therapeutics (FOLD) for $4.8 Billion - GuruFocus